Clinical trial
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or…
NCT01691898 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT01691898 |
|---|---|
| Title | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) |
| Official title | A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination… |
| Acronym | ROMULUS |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Follicular Lymphoma, Diffuse Large B-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin, Rituximab |
| Enrollment | 231 |
| Start date | Sep 27, 2012 |
| Primary completion | Mar 8, 2017 |
| Completion | Feb 7, 2019 |
| First posted | Sep 25, 2012 |
| Last update posted | Feb 21, 2020 |
| Countries | Canada, France, Germany, Italy, Netherlands, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: